202 related articles for article (PubMed ID: 32017443)
1. Prospective study of the relevance of circulating tumor cell status and neoadjuvant chemotherapy effectiveness in early breast cancer.
Ni C; Shen Y; Fang Q; Zhang M; Yuan H; Zhang J; Zhong M; Zheng Y
Cancer Med; 2020 Apr; 9(7):2290-2298. PubMed ID: 32017443
[TBL] [Abstract][Full Text] [Related]
2. Identification of the plasma total cfDNA level before and after chemotherapy as an indicator of the neoadjuvant chemotherapy response in locally advanced breast cancer.
Ma G; Wang J; Huang H; Han X; Xu J; Veeramootoo JS; Xia T; Wang S
Cancer Med; 2020 Apr; 9(7):2271-2282. PubMed ID: 32017472
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients.
Gwark S; Kim J; Kwon NJ; Kim KY; Kim Y; Lee CH; Kim YH; Kim MS; Hong SW; Choi MY; Jeon BH; Chang S; Yu J; Park JY; Lee HJ; Lee SB; Chung IY; Ko BS; Kim HJ; Lee JW; Son BH; Ahn JH; Jung KH; Kim SB; Gong GY; Ahn SH
Sci Rep; 2020 Oct; 10(1):17466. PubMed ID: 33060768
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Schramm A; Schochter F; Friedl TWP; de Gregorio N; Andergassen U; Alunni-Fabbroni M; Trapp E; Jaeger B; Heinrich G; Camara O; Decker T; Ober A; Mahner S; Fehm TN; Pantel K; Fasching PA; Schneeweiss A; Janni W; Rack BK;
Clin Breast Cancer; 2017 Jul; 17(4):279-285. PubMed ID: 28190761
[TBL] [Abstract][Full Text] [Related]
5. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
6. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.
Bidard FC; Michiels S; Riethdorf S; Mueller V; Esserman LJ; Lucci A; Naume B; Horiguchi J; Gisbert-Criado R; Sleijfer S; Toi M; Garcia-Saenz JA; Hartkopf A; Generali D; Rothé F; Smerage J; Muinelo-Romay L; Stebbing J; Viens P; Magbanua MJM; Hall CS; Engebraaten O; Takata D; Vidal-Martínez J; Onstenk W; Fujisawa N; Diaz-Rubio E; Taran FA; Cappelletti MR; Ignatiadis M; Proudhon C; Wolf DM; Bauldry JB; Borgen E; Nagaoka R; Carañana V; Kraan J; Maestro M; Brucker SY; Weber K; Reyal F; Amara D; Karhade MG; Mathiesen RR; Tokiniwa H; Llombart-Cussac A; Meddis A; Blanche P; d'Hollander K; Cottu P; Park JW; Loibl S; Latouche A; Pierga JY; Pantel K
J Natl Cancer Inst; 2018 Jun; 110(6):560-567. PubMed ID: 29659933
[TBL] [Abstract][Full Text] [Related]
7. Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China.
Lv M; Li B; Li Y; Mao X; Yao F; Jin F
Asian Pac J Cancer Prev; 2011; 12(9):2411-7. PubMed ID: 22296393
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial.
Gennari A; Foca F; Zamarchi R; Rocca A; Amadori D; De Censi A; Bologna A; Cavanna L; Gianni L; Scaltriti L; Rossi E; Facchinetti A; Martini V; Bruzzi P; Nanni O
Breast Cancer Res Treat; 2020 May; 181(1):61-68. PubMed ID: 32200486
[TBL] [Abstract][Full Text] [Related]
9. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
De La Cruz LM; Harhay MO; Zhang P; Ugras S
Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
[TBL] [Abstract][Full Text] [Related]
10. The impact of Oncotype DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer.
Soran A; Bhargava R; Johnson R; Ahrendt G; Bonaventura M; Diego E; McAuliffe PF; Serrano M; Menekse E; Sezgin E; McGuire KP
Breast Dis; 2016 Jul; 36(2-3):65-71. PubMed ID: 27662272
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.
Pierga JY; Bidard FC; Autret A; Petit T; Andre F; Dalenc F; Levy C; Ferrero JM; Romieu G; Bonneterre J; Lerebours F; Bachelot T; Kerbrat P; Campone M; Eymard JC; Mouret-Reynier MA; Gligorov J; Hardy-Bessard AC; Lortholary A; Soulie P; Boher JM; Proudhon C; Charafe-Jaufret E; Lemonnier J; Bertucci F; Viens P
Ann Oncol; 2017 Jan; 28(1):103-109. PubMed ID: 28177480
[TBL] [Abstract][Full Text] [Related]
12. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial.
Riethdorf S; Müller V; Zhang L; Rau T; Loibl S; Komor M; Roller M; Huober J; Fehm T; Schrader I; Hilfrich J; Holms F; Tesch H; Eidtmann H; Untch M; von Minckwitz G; Pantel K
Clin Cancer Res; 2010 May; 16(9):2634-45. PubMed ID: 20406831
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
[TBL] [Abstract][Full Text] [Related]
14. Predictive Value of Circulating Tumor Cells for Evaluating Short- and Long-Term Efficacy of Chemotherapy for Breast Cancer.
Ma S; Ling F; Gui A; Chen S; Sun Y; Li Z
Med Sci Monit; 2017 Oct; 23():4808-4816. PubMed ID: 28986517
[TBL] [Abstract][Full Text] [Related]
15. PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer.
Zhang Y; Liu M; Yang H; Wang J; Liu H; Li X; Li J; Xu J; Li X
Neoplasma; 2014; 61(4):461-7. PubMed ID: 25027743
[TBL] [Abstract][Full Text] [Related]
16. Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data.
Pierga JY; Petit T; Lévy C; Ferrero JM; Campone M; Gligorov J; Lerebours F; Roché H; Bachelot T; Charafe-Jauffret E; Bonneterre J; Hernandez J; Bidard FC; Viens P
Clin Cancer Res; 2015 Mar; 21(6):1298-304. PubMed ID: 25538259
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor.
Beije N; Onstenk W; Kraan J; Sieuwerts AM; Hamberg P; Dirix LY; Brouwer A; de Jongh FE; Jager A; Seynaeve CM; Van NM; Foekens JA; Martens JW; Sleijfer S
Neoplasia; 2016 Nov; 18(11):647-653. PubMed ID: 27764697
[TBL] [Abstract][Full Text] [Related]
18. Concurrent neoadjuvant chemotherapy and estrogen deprivation in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (CBCSG-036): A randomized, controlled, multicenter trial.
Yu KD; Wu SY; Liu GY; Wu J; Di GH; Hu Z; Hou YF; Chen CM; Fan L; Tang LC; Shen ZZ; Wu KJ; Zhuang ZG; Zhang HW; Shao ZM
Cancer; 2019 Jul; 125(13):2185-2193. PubMed ID: 30892700
[TBL] [Abstract][Full Text] [Related]
19. Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial.
Hepp P; Andergassen U; Jäger B; Trapp E; Alunni-Fabbroni M; Friedl TW; Hecker N; Lorenz R; Fasching P; Schneeweiss A; Fehm T; Janni W; Rack B
Anticancer Res; 2016 Sep; 36(9):4771-6. PubMed ID: 27630326
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A
Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
